Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.36 |
| ▸ | PDE2A | O00408 | 7/20 | 0.36 |
| ▸ | DHFR | P00374 | 2/20 | 0.36 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | SCN4A | P35499 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12574787 | 1.00 | KDM4E (0.47) | KDM4EHRH4BACE1NPBWR1PDE10A | |
| SCHEMBL2020323 | 0.83 | KDM4E (0.49) | KDM4EBACE1NPBWR1PDE10APDE2A | |
| SCHEMBL2021762 | 0.83 | KDM4E (0.49) | KDM4EBACE1NPBWR1PDE10APDE2A | |
| SCHEMBL7935792 | 0.80 | KDM4E (0.43) | KDM4EHRH4PDE10APDE2A | |
| SCHEMBL12574606 | 0.80 | KDM4E (0.43) | KDM4EHRH4PDE10APDE2A | |
| SCHEMBL12574724 | 0.79 | KDM4E (0.50) | KDM4EBACE1PDE10A | |
| SCHEMBL7937741 | 0.79 | KDM4E (0.50) | KDM4EBACE1PDE10A | |
| SCHEMBL12574841 | 0.78 | PDE10A (0.40) | KDM4EPDE10APDE2ADHFRPDE7A | |
| SCHEMBL7934977 | 0.75 | NOS2 (0.32) | PDE10A | |
| SCHEMBL7938166 | 0.75 | NQO2 (0.40) | KDM4EBACE1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160206-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20110160206-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160206-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PDE10A, PDE12, PDE9A | KDM4E 322/4885HRH4 877/4885BACE1 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.